Phenylaspirinate

Phenylaspirinate

SCHEMBL25954

CC(=O)Oc1ccccc1C(=O)Oc1ccccc1

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 6/20 0.75
KDM4E B2RXH2 4/20 0.75
LMNA P02545 2/20 0.75
CYP1A2 P05177 2/20 0.75
CYP2C9 P11712 2/20 0.75
PTGS2 P35354 4/20 0.68
ALDH1A1 P00352 4/20 0.68
HPGD P15428 4/20 0.68
TSHR P16473 2/20 0.68
TDP1 Q9NUW8 2/20 0.68
ESR1 P03372 1/20 0.68
ITGB3 P05106 1/20 0.68
ITGA2B P08514 1/20 0.68
HMGB1 P09429 1/20 0.68
GGT1 P19440 1/20 0.68
PTGS1 P23219 1/20 0.68
BLM P54132 1/20 0.68
NAPRT Q6XQN6 1/20 0.68
KMT2A Q03164 1/20 0.60
MAPT P10636 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylaspirinate SCHEMBL29389369 1.00 HSD17B10 (0.75) HSD17B10KDM4ELMNACYP1A2CYP2C9
SCHEMBL21449134 0.88 PTGS2 (0.68) HSD17B10KDM4ELMNACYP1A2CYP2C9
Diplosalsalate SCHEMBL25398 0.86 KDM4E (1.00) HSD17B10KDM4ELMNACYP1A2CYP2C9
SCHEMBL2473332 0.86 KDM4E (1.00) HSD17B10KDM4ELMNACYP1A2CYP2C9
Diplosalsalate SCHEMBL30590970 0.86 KDM4E (1.00) HSD17B10KDM4ELMNACYP1A2CYP2C9
SCHEMBL1282647 0.85 HSD17B10 (0.64) HSD17B10KDM4ELMNACYP1A2CYP2C9
SCHEMBL5710896 0.85 HSD17B10 (0.64) HSD17B10KDM4ELMNACYP1A2CYP2C9
SCHEMBL21526685 0.85 HSD17B10 (0.56) HSD17B10KDM4ELMNACYP1A2CYP2C9
SCHEMBL2887992 0.84 PTGS2 (0.63) HSD17B10KDM4ELMNACYP1A2CYP2C9
SCHEMBL15267403 0.84 PTGS2 (0.63) HSD17B10KDM4ELMNACYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1904 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240041935-A1 PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS CREATIVE MEDICAL TECHNOLOGIES, INC. (US) 2024-02-08 US claimed
US-20210145763-A1 LOW THC HEMP EXTRACT AND METHOD OF TREATMENT OR PREVENTION OF AN EYE DISEASE EYE CO PTY LTD. (AU) 2021-05-20 US claimed
EP-3773651-A1 LOW THC HEMP EXTRACT AND METHOD OF TREATMENT OR PREVENTION OF AN EYE DISEASE Eye Co Pty Ltd. (AU) 2021-02-17 EP claimed
WO-2019191800-A1 LOW THC HEMP EXTRACT AND METHOD OF TREATMENT OR PREVENTION OF AN EYE DISEASE EYE CO PTY LTD (AU) 2019-10-10 WO claimed
EP-2822532-B1 AQUEOUS POLYURETHANE DISPERSION IN THE TREATMENT OF ACNE COVESTRO DEUTSCHLAND AG (DE) 2018-09-19 EP claimed
CN-104529781-A A synthetic method of a chiral liquid crystal monomer, a cross-linking agent and an elastomer of the monomer PRODUCT QUALITY SUPERVISING AND INSPECTING INST OF TAIZHOU CITY 2015-04-22 CN claimed
US-20150080352-A1 AQUEOUS POLYURETHANE DISPERSION IN THE TREATMENT OF ACNE BAYER MATERIALSCIENCE LLC (US) 2015-03-19 US claimed
EP-2822532-A2 AQUEOUS POLYURETHANE DISPERSION IN THE TREATMENT OF ACNE Bayer Intellectual Property GmbH (DE) 2015-01-14 EP claimed
WO-2013131969-A2 EFFECT OF THE POLYURETHANE FILM FORMER ON THE EFFICACY OF ACNE TREATMENT BAYER MATERIALSCIENCE LLC (US) 2013-09-12 WO claimed
US-8361492-B2 Drug delivery system and methods of use Ocugenics, LLC (US) 2013-01-29 US claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0792371-A4 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO INC (US) 1998-12-30 EP claimed
EP-0880509-A1 2,4-DIAMINO-1,3,5-TRIAZINES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND PLANT-GROWTH REGULATORS Hoechst Schering AgrEvo GmbH (DE) 1998-12-02 EP claimed
WO-1998020864-A9 USE OF SELECTED NON-STEROIDAL ANTIINFLAMMATORY COMPOUNDS FOR THE PREVENTION AND THE TREATMENT OF NEURODEGENERATIVE DISEASES 1998-08-27 WO claimed
WO-1998020864-A2 USE OF SELECTED NON-STEROIDAL ANTIINFLAMMATORY COMPOUNDS FOR THE PREVENTION AND THE TREATMENT OF NEURODEGENERATIVE DISEASES UNIVERSITA' DEGLI STUDI DI BRESCIA - DIPARTIMENTO DI SCIENZE BIOMEDICHE (IT) 1998-05-22 WO claimed
EP-0792371-A1 COMBINATION METHOD FOR ACNE TREATMENT Merck & Co., Inc. (US) 1997-09-03 EP claimed
WO-1997029095-A1 2,4-DIAMINO-1,3,5-TRIAZINES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND PLANT-GROWTH REGULATORS HOECHST SCHERING AGREVO GMBH (DE) 1997-08-14 WO claimed
US-5543417-A 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent MERCK & CO., INC. (US) 1996-08-06 US claimed
WO-1996012817-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
EP-0450097-B1 BENZOHETEROCYCLIC COMPOUNDS OTSUKA PHARMA CO LTD (JP) 1996-04-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080352-A1 AQUEOUS POLYURETHANE DISPERSION IN THE TREATMENT OF ACNE UROD, CUTA, PUF60 HSD17B10 22/4885KDM4E 4264/4885LMNA 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.